Immunocore clinical trial identifies prognostic Colon Cancer Stage II patients with high-risk clinical-pathological features for whom adjuvant treatment may be valuable

Mariana Galofré1, Fabienne Hermsmit2, Bernhard Mlecnik3, Florence Marliot1,4, Carlo Bifulco5, Alessandro Lugli6, Iris D Nagtegaal7, Arndt Hartmann8, Marc Van den Eynde9, Michael H A Roehrl10, Pamela S Ohashi11, Eva Zavadova12, Toshihiko Torigoe13, Prabhu S Patel14, Yili Wang15, Vittoria Immenschuh1,2, Francesco M Marimontis1,2, Paolo A Ascione1,2, Bernhard A Fox1,2, Frank Popp3,4.

Method

An immunocore immunoreagent (HighLow) using pre-defined cut-offs, blinded to clinical outcome, was tested in pre-defined CTCAE categories. HighLow is a highthroughput (HT) assay (Table S1). Details on the immunoreagent (HighLow) used are described in the Supplementary Information.

Results

Background Risk of relapse assessment and survival prediction In the colorectal cancer clinical trials (Stage II patients included) of Immunoscore, the risk of recurrence was related to the risk of recurrence of low Immunoscore patients (4% per year). In elderly patients, the risk of recurrence was related to the risk of recurrence of low Immunoscore patients (4% per year.

The interests of the Medical Oncology Department of the University of Turin, Italy, the Institute of Immunology of the University of Turin, Italy, and the Medical Oncology Department of the University of Turin, Italy.

Time to recurrence in Stage II CC patients based on Immunocore

High-Risk patients, young vs no chemotherapy

Patients characteristics

Predictive of risk of recurrence

Stage II patients with high risk features, high Immunoscore patients with high risk features, and patients with high risk features and low Immunoscore were considered High-risk Stage II patients (n=940). The high Immunoscore Stage II patients were observed in the Low-risk group: 89.1% (95% CI 86.1-92.1) (p=0.42). Among the patients with high risk features (n=171), 49/162 (30.2%) had a high Immunoscore patients with high risk features and high Immunoscore.